Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates | Zendy

Jeffrey R. Crosby | Zendy; Ulla M. Marzec | Zendy; Alexey S. Revenko | Zendy; Chenguang Zhao | Zendy; Dacao Gao | Zendy; Anton Matafonov | Zendy; David Gailani | Zendy; A. Robert MacLeod | Zendy; Erik I. Tucker | Zendy; András Gruber | Zendy; Stephen R. Hanson | Zendy; Brett P. Monia | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates

Author(s) -

Jeffrey R. Crosby,

Ulla M. Marzec,

Alexey S. Revenko,

Chenguang Zhao,

Dacao Gao,

Anton Matafonov,

David Gailani,

A. Robert MacLeod,

Erik I. Tucker,

András Gruber,

Stephen R. Hanson,

Brett P. Monia

Publication year - 2013

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.113.301282

Subject(s) - antithrombotic , hemostasis , coagulation , medicine , pharmacology , fibrinolytic agent , immunology , thrombosis

During coagulation, factor IX (FIX) is activated by 2 distinct mechanisms mediated by the active proteases of either FVIIa or FXIa. Both coagulation factors may contribute to thrombosis; FXI, however, plays only a limited role in the arrest of bleeding. Therefore, therapeutic targeting of FXI may produce an antithrombotic effect with relatively low hemostatic risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research